Skip to content

S. 1818 · 119th Congress (2025–2027)

Prescription Drug Price Relief Act of 2025

This bill requires the Department of Health and Human Services (HHS) to review brand-name drugs annually for excessive pricing and, if a drug is found to be priced excessively, to void any exclusivity granted to its sponsor.

Specifically, HHS must review all brand-name drug prices at least annually and upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.

An entity accepting an open, nonexclusive license under these provisions must pay a reasonable royalty to the holder of the relevant patent or approved new drug application, and must price the generic drug or biosimilar below the excessive rate.

Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of these countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population.

The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

Show official title

A bill to significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is S. 1818’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. Bernard Sanders (I-VT)
Cosponsors
7 cosponsors

6 original · 1 later

7 D

  1. Sen. Richard Blumenthal (D-CT)· Original · May 20, 2025
  2. Sen. Cory A. Booker (D-NJ)· Original · May 20, 2025
  3. Sen. Christopher Murphy (D-CT)· Original · May 20, 2025
  4. Sen. Jeff Merkley (D-OR)· Original · May 20, 2025
  5. Sen. Peter Welch (D-VT)· Original · May 20, 2025
  6. Sen. Elizabeth Warren (D-MA)· Original · May 20, 2025
  7. Sen. Sheldon Whitehouse (D-RI)· Later · Jun 17, 2025
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred May 20, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (2)
  1. Prescription Drug Price Relief Act of 2025

    Display title, Short title · Introduced in Senate

  2. A bill to significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.

    Official title · Introduced in Senate